Negative EMA opinion for the ipilimumab/nivolumab combination

Yesterday it was announced that the combination of ipilimumab and nivolumab has not been recommended by the Committee for Medicinal Products for Human Use (CHMP), the scientific committee of the European Medicines Agency (EMA), for the first-line treatment of metastatic renal cell carcinoma (RCC). Bristol-Myers Squibb (BMS), the manufacturers of both ipilimumab and nivolumab, will be pursuing […]

read more

First-line tivozanib approved for use in NHS Scotland

We are delighted that the Scottish Medicines Consortium (SMC), which reviews newly licensed medicines, has published advice recommending tivozanib (Fotivda) as a new first-line treatment option for people with advanced renal cell carcinoma (RCC) for use within NHS Scotland. Tivozanib, a tyrosine kinase inhibitor, was accepted following consideration through the SMC’s Patient and Clinician Engagement (PACE) process, which is […]

read more

NICE set to decline first-line cabozantinib for advanced kidney cancer

The National Institute for Health and Care Excellence (NICE) have issued an interim decision not to recommend cabozantinib (Cabometyx®) as a first-line treatment for advanced kidney cancer, despite it’s proven effectiveness at prolonging the life of kidney cancer patients. In their Appraisal Consultation Document (ACD) released this week, NICE have made the decision cabozantinib is too expensive to be prescribed […]

read more

European Medicines Agency approves first-line cabozantinib for advanced kidney cancer

Cabozantinib (Cabometyx) has been granted approval by the Committee for Medicinal Products for Human Use (CHMP), the scientific committee of the European Medicines Agency (EMA), for previously untreated patients who have intermediate- or poor-risk advanced renal cell carcinoma (RCC). The CHMP positive opinion will now be reviewed by the European Commission (EC), which has the authority to […]

read more

Ipilimumab-nivolumab combination improves overall survival in metastatic kidney cancer

Overall survival data for the ipilimumab-nivolumab combination versus sunitinib from the phase 3 CheckMate-214 clinical trial have been published online in the New England Journal of Medicine.  Patients with intermediate-risk or poor-risk clear cell renal cell carcinoma (RCC) respond better and survive longer with first-line treatment with the ipilimumab-nivolumab combination than with standard sunitinib treatment. Overall survival rates […]

read more

First-line immunotherapy for metastatic kidney cancer

The following is a Practice Update interview with Dr Eric Jonasch, Professor of genitourinary medical oncology at the University of Texas MD Anderson Cancer Center, Houston, Texas. During this interview, Dr Jonasch talks about the upcoming immunotherapy combinations for use in the first-line for the treatment of metastatic renal cell carcinoma (mRCC), as well as […]

read more

US Food and Drug Administration approves frontline cabozantinib for advanced kidney cancer

Cabozantinib (Cabometyx) has been granted approval by the US Food and Drug Administration (FDA) for previously untreated patients who have advanced renal cell carcinoma (RCC). The approval is based on data from the phase 2 CABOSUN trial, that showed improvements in progression-free survival (PFS) for patients on cabozantinib compared to those who were given sunitinib […]

read more

First-line treatment for metastatic kidney cancer – an interview with Dr Eric Jonasch

The following is an interview with Dr Eric Jonasch, Professor in the Department of Genitourinary Medical Oncology, Division of Cancer Medicine, at the MD Anderson Cancer Center of The University of Texas in Houston, USA, where he is also Co-Chair of the Renal Cancer Program. Dr Jonasch discusses the data on the efficacy of new […]

read more
Showing 31 to 38 of 38 results
  TOP